About Us

Morgan Stanley GIFT CuresSM provides an opportunity for medical philanthropists to combine their contributions to magnify the impact of their giving, particularly for those concerned with advancing cures to life-threatening and life-altering diseases.

Our Story

Our Story

Introducing Morgan Stanley GIFT CuresSM powered by Harrington Discovery Institute

We live in the greatest era of scientific advancement in recorded history. The billions of dollars of public, private and philanthropic investment in medical research continues to yield groundbreaking insights into the causes and characteristics of our most persistent diseases. As patients and their families look to be part of the solution through their charitable donations, the field of philanthropy in particular has played a large role in advancing medical discoveries.

Morgan Stanley Global Impact Funding Trust (GIFT), established in 2000, is one of those players. After 19 years of working with the firm’s most dedicated and sophisticated philanthropists, Morgan Stanley GIFT realized that despite the generosity of donors within the Morgan Stanley GIFT community and around the world, there are far too many patients and families struggling with diseases for which there are no cures or meaningful treatments.

Morgan Stanley GIFT CuresSM, powered by Harrington Discovery Institute, was created in response to client demands for concrete results and outcomes from their philanthropy in disease research.

Record Giving; Too Few Cures

State of Diseases and Cure Research

500 treatments exist for roughly 10,000+ diseases

$38.3 billion in donations were made to health organizations in 2017, a record for the industry

20,000 nonprofits in the U.S. are dedicated to disease research

133 million Americans are affected by chronic disease

350 million people globally suffer from a rare disease

95% of rare diseases lack an FDA approved treatment

80-90% of research never reaches clinical testing

$2.6 billion is the estimated cost to develop one new drug

15-20 years is the estimated time for a drug to get to market

Our Approach

Our Approach

Supporting Basic Research Through Drug Development

Harrington Discovery Institute has developed a unique solution to drive early-stage discoveries toward a better chance of success:

  1. Source thousands of medical discoveries through an open call for submissions annually from prominent research universities and medical centers throughout the U.S., Canada, and the UK, creating a treasure trove of potential breakthroughs.
  2. Enlist eminent scientists and pharma executives to help identify the discoveries with the greatest potential to yield viable therapeutic advances across multiple diseases.
  3. "De-risk" those discoveries by providing development infrastructure, expertise, and financial support to move them through the earlier stages of the therapeutic pipeline.
  4. Support the researchers through the process with a dedicated team of experts to provide the management, marketing and clinical trial experience needed to develop therapies to the point where they are commercially attractive.